U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778407) titled 'TDXD in Metastatic HER2-Positive Breast Cancer' on Aug. 17.
Brief Summary: A single-center observational study (retrospective + prospective) evaluating the real-world efficacy and toxicity profile of Trastuzumab Deruxtecan (T-DXd) in adult female patients with HER2-positive metastatic breast cancer treated at KSAMC, Madinah, Saudi Arabia
Study Start Date: Feb. 01, 2023
Study Type: OBSERVATIONAL
Condition:
Breast Advanced Malignancies
Intervention:
DRUG: Trastuzumab deruxtecan (T-DXd)
Dose 5.4 mg/kg IV Frequency Every 3 weeks (Q3W) Route Intravenous infusion Line of Therapy 2nd line (post-adjuvant progression) or 3rd line and ...